SPOTLIGHT: Positive Velcade data fuels stock rise


Shares of Millennium Pharmaceuticals shot up this morning after the company announced that a late-stage trial of Velcade proved effective against multiple myeloma. Researchers stopped the trial so that all the participants could receive the drug, which is also being developed for non-Hodgkin's lymphoma. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.